TABLE 3
FROM:
Analysing DNA patents in relation with diagnostic genetic testing
Birgit Verbeure, Gert Matthijs and Geertrui Van Overwalle
BACK TO ARTICLETable 3. Classification template for the subject matter covered by the claims with application to the BRCA1 and BRCA2 patents (A): Different categories of claims covering product, method or use claims. (B): classification of European patents related to the BRCA1 and BRCA2 gene
| A | B | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| BRCA1 | BRCA2 | ||||||||||
| EP0699754 [1] 11.08.1995 a | EP0705902 [1] 11.08.1995 a | EP0705903 [1] 11.08.1995 a | EP0820526 [2] 12.02.1997 a | EP0821733 [3] 19.04.1996 a | EP0785216 [1] 17.12.1996 a | EP0858467 [4] 25.11.1996 a | |||||
| I | Product | ||||||||||
| Locus-related sequences | |||||||||||
| 1 | Markers | ||||||||||
| Nucleic acid | |||||||||||
| 2 | cDNA | 1, 2 | 1 | 1, 2 | 3, 4 | ||||||
| 3 | Individual exons | ||||||||||
| 4 | Individual exons with flanking intron | 1, 2 | |||||||||
| 5 | Genomic sequence | ||||||||||
| 6 | Complementary seq. | 5 | |||||||||
| 7 | Fragment | 1, 5 | |||||||||
| 8 | Primers/probes | 6, 7, 8 | 1 | 3, 31 | 1b | 6 | |||||
| Variation/mutation | |||||||||||
| 9 | % Identical/variation | 3 | |||||||||
| 10 | Nonspecific mutation | ||||||||||
| 11 | Specific mutation | 4 | 1, 2, 30 | 1–5 | 3, 4, 5 | ||||||
| Peptide | |||||||||||
| 12 | Wild type | 15–16, 18, 21 | 2 | 11 (full), 12 and 13 (fragment) | |||||||
| 13 | Mutated | 17, 18, 21, 22 | 13 | 6–10 | |||||||
| 14 | Antibody | 19, 20 | |||||||||
| Diagnostic kit comprising: | |||||||||||
| 15 | Nucleic acid | 25, 26 | |||||||||
| 16 | Peptide | ||||||||||
| 17 | Antibody | ||||||||||
| Composition/preparation | |||||||||||
| 18 | Nucleic acid | ||||||||||
| 19 | Peptide | 9–11, 12, 32 | 11, 12 | ||||||||
| Purpose-limited product | |||||||||||
| 20 | Nucleic acid | 27 | 16 | 10 | |||||||
| 21 | Peptide | 29 | 14 | ||||||||
| Recombinant technology | |||||||||||
| 22 | Vector | 9, 10, 11 | 2 | 4, 5 | 2b | 7 | 6 | ||||
| 23 | Host | 12 | 3 | 6 | 3b | 8 | 7 | ||||
| 24 | Peptide | ||||||||||
| 25 | Antibody | 15 | |||||||||
| 26 | Organism producing Ab | ||||||||||
| 27 | Transgenic organism | 34 | |||||||||
| II | Method | ||||||||||
| Determination of a variation | |||||||||||
| 1 | Mutation not specified | 15 | |||||||||
| 2 | Mutation specified | ||||||||||
| Diagnostic method (NA) | |||||||||||
| 3 | Linkage analysis | ||||||||||
| 4 | Mutation scanning | 1, 2, 3–8, 14, 15, 17, 18, 21–23 | 3, 4, 5, 6c | 16 d | |||||||
| 5 | Mutation analysis | 9, 16, 19, 20, 24 | 16, 17, 18–29, 33 | 11 | |||||||
| 6 | Quantitative | 25, 26, 27–28 | |||||||||
| 7 | Diagnostic method peptide | 5, 10–13, 25–27, 29 | 19 | 12 | 16 | ||||||
| 8 | Diagnostic method antibody | ||||||||||
| 9 | Recombinant expression | 13, 14 | 7, 8 | 9, 10 | 8, 9 | ||||||
| 10 | Screening for therapeutics | 31, 32, 33 | |||||||||
| III | Use | ||||||||||
| medical use: treatment | |||||||||||
| 1 | As such | ||||||||||
| 2 | Disease oriented | 17 (NA) 18 (pept) | |||||||||
| 3 | Method oriented | 28 (NA), 30 (pept) | 7 (NA) 8 (pept) | ||||||||
| Medical use: diagnostic | |||||||||||
| 4 | As such | ||||||||||
| 5 | Disease oriented | 1 | |||||||||
| 6 | Method oriented | ||||||||||
| Use in recombinant technology | |||||||||||
| 7 | Of nucleic acid | ||||||||||
| 8 | Of peptide | 23, 24 | 14, 15 | 13, 14 | |||||||
Independent claims are in bold. Claims in the patents as originally granted but revoked or amended during opposition procedures at the EPO are in italic and separated from the current enforceable set of claims by a dotted line. [1] The patent has been jointly filed by Myriad Genetics, the University of Utah Research Foundation and the United States of America. Recently, Myriad Genetics transferred its rights on the invention in Europe over to the University of Utah Research Foundation; [2] The patent was originally filed by Oncormed that has been taken over by Gene Logic; [3] The patent proprietor is the Regents of the University of California; [4] the patent was originally filed by Cancer Research Campaign Technology Limited and Duke University, the former merged with the Imperial Cancer Research Fund and formed Cancer Research UK.
a Date of filing the patent application.
b Claim refers to one specific mutation only (185delAG).
c Claim disclaims diagnostic methods determining mutations known in prior art.
d Claim covers mutation scanning in part of the BRCA2 gene only.
(NA): method or use based on the nucleic acid, (pept): method or use based on the peptide.
